Time for international action on treating testosterone deficiency syndrome

References

• Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med 2008; 5: 998–1012
   PubMed Web of Science ®Google Scholar
• Andersson A M, Jensen T K, Juul A, Petersen J H, Jorgensen T, Skakkebaek N E. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab 2007; 92: 4696–4705
   PubMed Web of Science ®Google Scholar
• Araujo A B, Esche G R, Kupelian V, O'donnell A B, Travison T G, Williams R E, Clark R V, McKinlay J B. Prevalence of symptomatic androgen deficiency in Men. J Clin Endocrinol Metab 2007; 93: 4241–4247
   Google Scholar
• Andersson A M, Bay K, Grigor K M, Toppari J, Skakkabaek N E. Proceedings of the 4th Copenhagen workshop on endocrine disruptors. Int J Androl 2008; 31: 73–293
   Web of Science ®Google Scholar
• Jones R D, Malkin C J, Channer K S, Jones T H. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: further supportive data. J Clin Endocrinol Metab 2003; 88: 1403–1404
   PubMed Web of Science ®Google Scholar
• Khaw K T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007; 116: 2694–2701
   PubMed Web of Science ®Google Scholar
• Kapoor D, Jones T. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention. Drugs Aging 2008; 25: 357–369
   PubMed Web of Science ®Google Scholar
• Guay A T, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 2007; 4: 1046–1055
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas M, Panagiotopoulos S, Sharpe K, Macisaac R, Clarke S, Zajac J, Jerums G. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93: 1834–1840
   PubMed Web of Science ®Google Scholar
• Fukui M, Soh J, Tanaka M, Kitagawa Y, Hasegawa G, Yoshikawa T, Miki T, Nakamura N. Low serum testosterone concentration in middle-aged men with type 2 diabetes. Endocr J 2007; 54: 871–877
   PubMed Web of Science ®Google Scholar
• Meier C, Nguyen T V, Handelsman D J, Schindler C, Kushnir M M, Rockwood A L, Meikle A W, Center J R, Eisman J A, Seibel M J. Endogenous sex hormones and incident fracture risk in older men: the Dubbo osteoporosis epidemiology study. Arch Intern Med 2008; 168: 47–54
   PubMed Web of Science ®Google Scholar
• Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003; 60: 21–28
   PubMed Web of Science ®Google Scholar
• Mohr B A, Bhasin S, Kupelian V, Araujo A B, O'donnell A B, McKinlay J B. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc 2007; 55: 548–555
   PubMed Web of Science ®Google Scholar
• Morley J E, Haren M T, Rolland Y, Kim M J. Frailty. Med Clin North Am 2006; 90: 837–847
   PubMed Web of Science ®Google Scholar
• Bates K A, Harvey A R, Carruthers M, Martins R N. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. Cell Mol Life Sci 2005; 62: 281–292
   PubMed Web of Science ®Google Scholar
• Tan R S, Culberson J W. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 2003; 45: 15–27
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Lehmann D J, Warden D R, McBroom J, Smith A D. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer's disease in men. Int J Geriatr Psychiatry 2002; 17: 938–940
   PubMed Web of Science ®Google Scholar
• Shores M M, Matsumoto A M, Sloan K L, Kivlahan D R. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660–1665
   PubMed Web of Science ®Google Scholar
• Laughlin G A, Barrett C, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68–75
   PubMed Web of Science ®Google Scholar
• Wu F C, Tajar A, Pye S R, Silman A J, Finn J D, O'Neill T W, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi I T, Kula K, Punab M, Boonen S, Vanderschueren D. Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab 2008; 93: 2737–2745
   PubMed Web of Science ®Google Scholar
• Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. Curr Opin Investig Drugs 2003; 4: 1213–1219
   PubMedGoogle Scholar
• Carruthers M, Trinick T R, Wheeler M J. The validity of androgen assays. Aging Male 2007; 10: 165–172
   PubMed Web of Science ®Google Scholar
• Heinemann L AJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms' (AMS) rating scale. Aging Male 1999; 2: 105–114
   Google Scholar
• Heinemann L A, Saad F, Heinemann K, Thai D M. Can results of the aging males' symptoms (AMS) scale predict those of screening scales for androgen deficiency. Aging Male 2004; 7: 211–218
   PubMedGoogle Scholar
• Heinemann L A. Aging males' symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005; 28: 34–38
   PubMedGoogle Scholar
• Heinemann L AJ, Saad F, Thiele K. The Aging males' symptoms rating scale: cultural and linguistic validation into English. Aging Male 2001; 4: 14–22
   Google Scholar
• Daig I, Heinemann L A, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai D M. The aging males' symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003; 1: 77
   PubMedGoogle Scholar
• Moore C, Huebler D, Zimmermann T, Heinemann L A, Saad F, Thai dM. The aging males' symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80–87
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Moore C, Dinger J C, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health Qual Life Outcomes 2006; 4: 23
   PubMed Web of Science ®Google Scholar
• Morley J E, Charlton E, Patrick P, Kaiser F E, Cadeau P, McCready D, Perry H M. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–1242
   PubMed Web of Science ®Google Scholar
• Carruthers M. ADAM: androgen deficiency in the adult male – causes, diagnosis and treatment. Taylor & Francis, London, New York 2004
   Google Scholar
• Corona G, Mannucci E, Petrone L, Balercia G, Fisher A D, Chiarini V, Forti G, Maggi M. ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006; 3: 706–715
   PubMed Web of Science ®Google Scholar
• Abramsky L, Chapple J. 47,XXY (Klinefelter syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. Prenat Diagn 1997; 17: 363–368
   PubMed Web of Science ®Google Scholar
• Sijstermans K, Hack W W, Meijer R W, van der Voort-Doedens L M. The frequency of undescended testis from birth to adulthood: a review. Int J Androl 2008; 31: 1–11
   PubMed Web of Science ®Google Scholar
• Allan C A, McLachlan R I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf) 2004; 60: 653–670
   PubMed Web of Science ®Google Scholar
• Liverman C T, Blazer D G, Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and aging: clinical research directions. The National Academies Press, Washington, DC 2004
   Google Scholar
• Hall S A, Araujo A B, Esche G R, Williams R E, Clark R V, Travison T G, McKinlay J B. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med 2008; 168: 1070–1076
   PubMed Web of Science ®Google Scholar
• Jungwirth A, Plas E, Geurts P. Clinical experience with andriol testocaps–the first Austrian surveillance study on the treatment of late-onset hypogonadism. Aging Male 2007; 10: 183–187
   PubMed Web of Science ®Google Scholar
• Handelsman D J. Trends and regional differences in testosterone prescribing in Australia, 1991–2001. Med J Aust 2004; 181: 419–422
   PubMed Web of Science ®Google Scholar
• Spetz A CE, Palmefors L, Skobe R SP, Stroemstedt M T, Fredriksson M, Theodorsson E, Hammar M L. Testosterone correlated to symptoms of partial androgen deficiency in aging men (PADAM) in an elderly Swedish population. Menopause 2007; 14: 999–1005
   PubMed Web of Science ®Google Scholar
• McKinlay J B, Travison T G, Araujo A B, Kupelian V. Male menopause: time for a decent burial. Menopause 2007; 14: 973–975
   PubMed Web of Science ®Google Scholar
• Gooren L J, Behre H M, Saad F, Frank A, Schwerdt S. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male 2007; 10: 173–181
   Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125–127
   PubMed Web of Science ®Google Scholar
• Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005; 2: 759–770
   PubMed Web of Science ®Google Scholar
• Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 2008; 5: 1841–1865
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 935–939
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335–4343
   PubMed Web of Science ®Google Scholar
• Travison T G, Shackelton R, Araujo A B, Hall S A, Williams R E, Clark R V, O'donnell A B, McKinlay J B. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 2008; 56: 831–839
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham G R, Hayes F J, Matsumoto A M, Snyder P J, Swerdloff R S, Montori V M. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre H M. Testosterone therapy. Andrology: male reproductive health and dysfunction, E Neischlag, H M Behre. Springer, Berlin 1997; 295–309
   Google Scholar
• Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007; 4: 1056–1069
   PubMed Web of Science ®Google Scholar
• Cohen J T, Neumann P J, Weinstein M C. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008; 358: 661–663
   PubMed Web of Science ®Google Scholar